Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

60°
- Newport, VT (05855)
  Today
  
  Areas of patchy fog early. Partial cloudiness early, with scattered showers and thunderstorms during the afternoon. High 72F. Winds SSW at 5 to 10 mph. Chance of rain 40%..
  
  Tonight
  
  Partly cloudy skies this evening will become overcast overnight. Slight chance of a rain shower. Low near 55F. Winds light and variable.
  
  Updated: August 24, 2026 @ 4:30 am
- Full Forecast

Site search

Home
News
Sports
Entertainment
- Calendar
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
- Place an ad
Archives
Best of 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

77.39 +0.55 (+0.71%)

Streaming Delayed Price Updated: 2:31 PM EDT, Aug 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700 ↗

August 22, 2026

Blum exercised stock options at $10.60 and sold at $76.76, capturing significant appreciation.

Via The Motley Fool

Topics Regulatory Compliance

Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

MYQORZO captures 40% new-to-brand share with 1,500 dispensed patients.

Via The Motley Fool

Topics Earnings Economy

Cytokinetics Q2 Earnings Call Highlights ↗

August 06, 2026

Cytokinetics (NASDAQ:CYTK) reported second-quarter results marked by early commercial momentum for MYQORZO, international market-access progress and plans to seek an expanded indication for aficamten...

Via MarketBeat

Topics Earnings

Cytokinetics (NASDAQ:CYTK) Beats Q2 Estimates on Strong MYQORZO Launch ↗

August 06, 2026

Via Chartmill

Cytokinetics Inc. (NASDAQ:CYTK) Scores Strong Setup Quality for a Potential Breakout ↗

April 23, 2026

Via Chartmill

Cytokinetics Inc (NASDAQ:CYTK) Reports Strong Q4 Revenue Beat Amid Deepening Losses and Negative Market Reaction ↗

February 24, 2026

Via Chartmill

CYTOKINETICS INC (NASDAQ:CYTK) Shows Strong Technicals and High-Quality Breakout Setup ↗

February 14, 2026

Via Chartmill

Here's How Much $100 Invested In Cytokinetics 10 Years Ago Would Be Worth Today ↗

August 05, 2026

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.02% on an annualized basis producing an average annual return of 20.46%. Currently, Cytokinetics has a market...

Via Benzinga

Prediction: U.S. Small-Cap Stocks Will Beat Large Caps for 10 Years ↗

July 21, 2026

If you want to lock in future gains from today's small-cap stocks, these two ETFs could be good options.

Via The Motley Fool

Topics ETFs

What This Cytokinetics Insider Sale Might Mean With the Stock Up 110% ↗

July 14, 2026

Blum exercised options at $10.60 per share and immediately sold them at $82.02, capturing gains from a 122% stock surge over the past year. He retains 381,986 shares and maintains a 0.31% ownership...

Via The Motley Fool

Topics Regulatory Compliance

Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise ↗

May 22, 2026

Cytokinetics (NASDAQ:CYTK) executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug’s label, REMS...

Via MarketBeat

Cytokinetics (CYTK) Q1 2026 Earnings Transcript ↗

May 05, 2026

Cytokinetics (CYTK) Q1 2026 Earnings Transcript

Via The Motley Fool

Wondering what's happening in today's pre-market session? ↗

May 05, 2026

Via Chartmill

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗

March 23, 2026

This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗

March 21, 2026

This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

Via The Motley Fool

Topics Regulatory Compliance

This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗

March 21, 2026

This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.

Via The Motley Fool

Topics Regulatory Compliance

This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗

March 21, 2026

Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.

Via The Motley Fool

Topics Regulatory Compliance

DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗

March 21, 2026

iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but...

Via The Motley Fool

Topics Derivatives ETFs Regulatory Compliance

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗

March 20, 2026

This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.

Via The Motley Fool

Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market ↗

March 09, 2026

This biopharma company advancing cardiac drug candidates disclosed a notable insider sale amid late-stage clinical development.

Via The Motley Fool

Topics Regulatory Compliance

Cytokinetics (CYTK) Q4 2025 Earnings Transcript ↗

February 24, 2026

Cytokinetics (CYTK) Q4 2025 Earnings Transcript

Via The Motley Fool

European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO

February 23, 2026

In a landmark decision for the cardiovascular treatment landscape, the European Commission (EC) officially granted marketing authorization to Cytokinetics, Inc. (Nasdaq: CYTK) on February 17, 2026, for...

Via MarketMinute

Topics Intellectual Property

Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market

February 19, 2026

Cytokinetics, Inc. (Nasdaq: CYTK) has officially cleared its final major regulatory hurdle for its flagship heart failure drug, MYQORZO (aficamten), receiving marketing authorization from the European...

Via MarketMinute

The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A

January 16, 2026

As the global economy shakes off the final remnants of the high-interest-rate era, a massive wave of consolidation is sweeping through corporate boardrooms. Analysts have officially adjusted their...

Via MarketMinute

Topics Artificial Intelligence Economy

The Great Rebalancing: Small-Caps Surge as Big Tech Giants Stumble in Early 2026

January 02, 2026

The opening days of 2026 have ushered in a definitive regime shift in the global financial markets, as the long-awaited "Great Rotation" finally takes hold. After years of dominance by a handful of...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Cytokinetics Wins First FDA Approval For Heart Disease Drug — Why Is Wall Street Still Cautious? ↗

December 19, 2025

The FDA approved 5 mg, 10 mg, 15 mg, 20 mg Myqorzo tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Via Stocktwits

This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock? ↗

December 19, 2025

B. Lynne Parshall sold $323,650 worth of Cytokinetics shares in November.

Via The Motley Fool

Topics Regulatory Compliance

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗

December 08, 2025

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Via The Motley Fool

Topics Regulatory Compliance

What Does the Market Think About Cytokinetics Inc? ↗

November 18, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Entertainment
Obituaries
Local Events
Multimedia
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather
California Privacy Notice

Newport Daily Express

NewportVermontDailyExpress.com
178 Hill Street
Newport, VT 05855
Phone: 802-334-6568
Email: editor@newportvermontdailyexpress.com

Facebook

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Consent Preferences

Newport, VT (05855)

Today

Tonight

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

Headline News about Cytokinetics, Incorporated - Common Stock

Sections

Services

Newport Daily Express